Are we ready for home spirometry for systemic sclerosis-associated ILD?
Spirometry is central to monitoring progression of interstitial lung disease (ILD) associated with systemic sclerosis.1 A decline in the forced vital capacity (FVC) on spirometry is associated with an increased risk of mortality in patients with systemic sclerosis-associated ILD.2,3 Spirometry testing has historically been conducted under the supervision of trained professionals subject to specific proficiency standards. However, some clinical care systems, as well as clinical trials,4 have adopted unsupervised remote spirometry.
